Nocturnal rise of urinary thromboxane B2 in patients with coronary artery disease

Filippo L. Fimognari; Gianfranco Piccirillo; Jaime Lama; Paolo De Marzio; Sergio Morelli; Girolamo Monteleone; Vincenzo Mollace; Francesco Violi

doi:10.1055/s-0037-1616561

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2005; 93(03): 618-619
DOI: 10.1055/s-0037-1616561

Letters to the Editor

Schattauer GmbH

Nocturnal rise of urinary thromboxane B₂ in patients with coronary artery disease

Filippo L. Fimognari

¹The Division of Internal Medicine, Asl Roma G/Parodi-Delfino Hospital, Colleferro(Rome), Italy

,

Gianfranco Piccirillo

²The Department of Aging Science, University La Sapienza, Rome, Italy

,

Jaime Lama

³The Division of Internal Medicine, Nacional Hipoli to Unanue Hospital, Lima, Perù

,

Paolo De Marzio

⁴The Department of Internal Medicine, University La Sapienza, Rome, Italy

,

Sergio Morelli

⁴The Department of Internal Medicine, University La Sapienza, Rome, Italy

,

Girolamo Monteleone

⁵The Laboratory of Clinical Pathology, Asl 9/Del Balzo-Squillacioti Hospital, Locri (RC), Italy

,

Vincenzo Mollace

⁶The Faculty of Pharmacy, University of Catanzaro Magna Graecia, Roccellettadi Borgia (CZ), Italy

,

Francesco Violi

⁷The Division of IV Medical Clinic, University La Sapienza, Rome, Italy

› Author Affiliations

Abstract

Full Text

References

References
1 Muller JE, Toefler GH, Stone PH. Circadian variation and triggers of onset of acute cardiovascular disease. Circulation 1989; 79: 733-43.
2 Andreotti F, Davies GJ, Hackett DR et al. Major circadian fluctuations in fibrinolytic factors and possible relevance to time of onset of myocardial infarction, sudden cardiac death, and stroke. Am J Cardiol 1988; 62: 635-7.
3 Willich SN, Pohjola-Sintonen S, Bhatia SJS et al. Suppression of silent ischemia by metoprolol without alteration of morning increase of platelet aggregability in patients with stable coronary artery disease. Circulation 1987; 76: 488-91.
4 Tofler GH, Brezinski DA, Schafer A et al. Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden death. N Engl J Med 1987; 316: 1514-8.
5 Brezinski DA, Tofler GH, Muller JE et al. Morning increase in platelet aggregability. Association with upright posture. Circulation 1988; 78: 35-40.
6 Ridker PM, Manson JE, Buring JE et al. Circadian variation of acute myocardial infarction and the effect of a low-dose aspirin in a randomised trial of physicians. Circulation 1990; 82: 897-902.
7 Patrono C, Patrignani P, Rocca B et al. Characterization of biochemical and functional effects of antiplatelet drugs as a key to their clinical development. Thromb Haemost 1995; 74: 396-400.
8 Pradelles P, Grassi J, Maclouf J. Enzyme immunoassay of eicosanoids using acetylcholine esterase as label: an alternative to radioimmunoassay. Anal Chem 1985; 57: 1170-3.
9 Lellouch F, Fradin A, Fitzgerald GA. et al. Enzyme immunoassay measurement of the urinary metabolites of thromboxane A2 and prostacyclin. Prostaglandins 1990; 40: 297-310.
10 Davì G, Gresele P, Violi F et al. Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Circulation 1997; 96: 69-75.
11 Tohgi H, Konno S, Tamura K et al. Effects of lowto- high doses of aspirin on platelet aggregability and metabolites of thromboxane A2 and prostacyclin. Stroke 1992; 23: 1400-3.
12 Montalescot G, MacLouf J, Drobinski G et al. Eicosanoid biosynthesis in patients with stable angina: beneficial effects of very low dose aspirin. J Am Coll Cardiol 1994; 24: 33-8.
13 Belton O, Byrne D, Kearney D et al. Cyclooxygenase- 1 and –2 dependent prostacyclin formation in patients with atherosclerosis. Circulation 2000; 102: 840-5.
14 Kearney D, Byrne A, Crean P et al. Optimal suppression of thromboxane A2 formation by aspirin during percutaneous transluminal coronary angioplasty: no additional effect of a selective cyclooxygenase-2 inhibitor. J Am Coll Cardiol 2004; 43: 526-31.